{"name":"Orion Corporation","slug":"orion","ticker":"ORNBV.HE","exchange":"Nasdaq Helsinki","domain":"orion.fi","description":"Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterina","hq":"Espoo, Finland","founded":0,"employees":"4029","ceo":"Liisa Hurme","sector":"Oncology / CNS","stockPrice":71.7,"stockChange":0.9,"stockChangePercent":1.27,"marketCap":"$10.1B","metrics":{"revenue":1889500032,"revenueGrowth":60.1,"grossMargin":64.2,"rdSpend":0,"netIncome":500300000,"cash":160900000,"dividendYield":2.51,"peRatio":20.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Alunbrig patent cliff ($100.0M at risk)","drug":"Alunbrig","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Lartruvo patent cliff ($50.0M at risk)","drug":"Lartruvo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-02","type":"regulatory","headline":"Orion Corporation receives positive CHMP opinion for Lartruvo","summary":"The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Lartruvo, recommending its approval for the treatment of soft tissue sarcoma.","drugName":"Lartruvo","sentiment":"positive"},{"date":"2022-08-04","type":"earnings","headline":"Orion Corporation reports Q2 2022 results","summary":"Orion Corporation reported its Q2 2022 financial results, with net sales increasing by 10% compared to the same period last year.","drugName":"","sentiment":"neutral"},{"date":"2021-06-01","type":"deal","headline":"Orion Corporation partners with Pfizer to develop new cancer therapies","summary":"Orion Corporation has entered into a partnership with Pfizer to develop and commercialize new cancer therapies, expanding its presence in the oncology market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQand1WlZfMmhYS0NCbzVmXzFMX041a1dYOUJCdWtyZGVQTEt2eFZQa0xQSGZFSlV1T1VSOUNReml0WHlCaGxneHpDU1gxa0YtUmgxQUtOeTF0ZWk0Q3NIeFZUb3pXMGZyaGpZQzN6V3RFS0FMWVJxdGVtNURDVGNveFFkWTFUaldnaklUXy1YTTVFY0lYYnc?oc=5","date":"2026-03-19","type":"pipeline","source":"Yahoo Finance UK","summary":"Orion Corporation: Managers’ transactions – Outi Vaarala - Yahoo Finance UK","headline":"Orion Corporation: Managers’ transactions – Outi Vaarala","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNVVBKbXU5SUM5MEFUcUpZZ3Z0YkpsbURCQlNuVDZFZTNIWDRPVGlKTGxjZzFWUHRHd1g5TUg1UW1naFh3aXRtbVREcmxFNmNaTU5HaWtqWmNkQ2FOcndnNDVKNm5QNXdLc0Fucm4xdERDNlhubHhqV3BNdnJSazVCSHpLREFZTFFBX0owN0wyVk45QjM5?oc=5","date":"2026-03-10","type":"pipeline","source":"Yahoo Finance","summary":"Orion Corporation: Managers’ transactions – Satu Ahomäki - Yahoo Finance","headline":"Orion Corporation: Managers’ transactions – Satu Ahomäki","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOUFFMN2xlWkNUcUo5ZFNCZVUwWHRtTk9iT2Y2OGtZbzJiY3hWX29DRjVuZ0hCRWk5TGw3Qks5ZnZmMlFKOU15X3FfdUNnREFxVERhTnRnTUVKcWFCTlJPR1JOdDBNRm8xMkVjcDJ5NXJXWFNkbjdkNnV1V1RJT2VZaWVQR0NuckxSMHNWWnhvVWg?oc=5","date":"2026-02-27","type":"pipeline","source":"Yahoo Finance","summary":"Orion Group Financial Statement documents 2025 and Remuneration Report published - Yahoo Finance","headline":"Orion Group Financial Statement documents 2025 and Remuneration Report published","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQeWl6U3l5X01KeDZhbkFNQjNPaURaWEFHQk96cmpoWU9fRkdjN3RZZEpYRUxabmlwbHdSZUc3dkU2RmJNRDBFTi10MUJYUWR0eVJxZ1Z4T3ozdkJDTWM0aTVSaXpSbGZHMlRjeWlyQ05aLVpqR0oxbGhOZGY2S2ZZRDVBR2ttSUxvZkdnQmhrR2NGd2liYXk2dDVRREpJY2JCM1M2TnNOcw?oc=5","date":"2026-01-14","type":"pipeline","source":"Investing.com","summary":"Orion shares jump 12% after strong Nubeqa-led 2026 outlook - Investing.com","headline":"Orion shares jump 12% after strong Nubeqa-led 2026 outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFB3bWhOb3dydW1RYmF6eWxKd3dwXzR4QmRUTFRCRW52QkRKelNUajRicFQ5UGhTUjlDcVJnYTVER0tnaU96NFhQNTBBUU4wNFB2ek45MVRTaw?oc=5","date":"2017-05-19","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Orion Oyj (ORNBV.HE) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Orion Oyj (ORNBV.HE) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Alunbrig","drugSlug":"brigatinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Lartruvo","drugSlug":"lusutamab-vedotin","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["Oncology","Central Nervous System (CNS)"],"financials":null,"yahoo":{"currentPrice":71.7,"previousClose":70.8,"fiftyTwoWeekHigh":75.3,"fiftyTwoWeekLow":46.62,"fiftyTwoWeekRange":"46.62 - 75.3","fiftyDayAverage":69.61,"twoHundredDayAverage":66.3,"beta":0.3,"enterpriseValue":10105587712,"forwardPE":16.8,"priceToBook":7.85,"priceToSales":5.35,"enterpriseToRevenue":5.35,"enterpriseToEbitda":14.82,"pegRatio":0,"ebitda":681800000,"ebitdaMargin":36.1,"freeCashflow":124150000,"operatingCashflow":316800000,"totalDebt":305400000,"debtToEquity":23.8,"currentRatio":2.4,"returnOnAssets":21.7,"returnOnEquity":43.7,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":73,"targetHighPrice":80,"targetLowPrice":55,"dividendRate":1.8,"payoutRatio":0.46,"fiveYearAvgDividendYield":3.34,"exDividendDate":1792368000,"insiderHeldPercent":2.6,"institutionHeldPercent":37.9,"sharesOutstanding":109341372,"floatShares":122956125,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":3.56,"epsForward":4.27,"revenuePerShare":13.43,"bookValue":9.13,"officers":[{"age":58,"name":"Dr. Liisa  Hurme Ph.D.","title":"President, CEO & Chairman of Executive Management Board"},{"age":49,"name":"Mr. Rene  Lindell M.Sc., Ph.D.","title":"CFO & Member of Group Executive Management Board"},{"age":59,"name":"Ms. Satu  Ahomäki M.Sc., M.Sc. (Econ.)","title":"Executive VP of Generics and Consumer Health & Member of the Exe. Mgmt. Board"},{"age":63,"name":"Prof. Outi  Vaarala M.D., Ph.D.","title":"Executive VP of Innovative Medicines and R&D and Member of the Exe. Mgmt. Board"},{"age":45,"name":"Mr. Juhani  Kankaanpaa M.Sc.","title":"Executive VP of Global Operations & Member of Executive Management Board"},{"age":59,"name":"Mr. Niclas  Lindstedt EMBA, M.Sc.","title":"Executive VP of Animal Health & Member of the Exe. Mgmt. Board"},{"age":54,"name":"Mr. Hao  Pan M.Sc.","title":"Executive VP of the Branded Products & Member of the Exe. Mgmt. Board"},{"age":48,"name":"Ms. Julia Irene Macharey","title":"Executive VP of People & Culture & Member of Management Board"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.orionpharma.com","phone":"358 10 4261"}}